The Therapeutic Goods Administration has added Foundayo (orforglipron) to the Australian Register of Therapeutic Goods to help tackle the nation’s obesity and type 2 diabetes epidemics.1-3
Foundayo from Lilly is a first-of-its-kind small-molecule, non-peptide GLP-1 receptor agonist that works by targeting and stimulating a natural hormone in the body (the glucagon-like peptide-1) to control hunger, slow digestion and promote feelings of fullness.1
“Australia is grappling with rising rates of overweight and obesity, which now affect around 13 million adults”
Associate Professor Samantha Hocking, President of the National Association of Clinical Obesity Services, welcomed the availability of the new medicine, noting that overweight and obesity had overtaken smoking as the leading risk factor for disease burden in Australia.4
“Australia is grappling with rising rates of overweight and obesity, which now affect around 13 million adults,”2 Dr Hocking said.
“Obesity is a complex chronic disease that increases the risk of at least 30 other serious medical conditions, ranging from cancer and cardiovascular disease to type 2 diabetes.2
“The impact of obesity and type 2 diabetes on individuals, families and our health system highlights the urgent need for stronger prevention efforts and improved access to clinically proven treatment options.”
Dr Hocking noted entrenched misconceptions about weight, including that obesity stems from a lack of willpower.
“For many people, eating less and moving more isn’t enough to sustain meaningful weight loss in the face of a disease caused by a combination of genetic, physiological, behavioural and environmental factors,” she said.
“Medication can play an important role in helping people achieve and maintain a healthier weight but must be accompanied by a healthy diet and exercise.”
Lilly Australia General Manager Dr Manny Simons said Foundayo was the result of more than a decade of clinical research and development.5
He said “Foundayo clinical trials involved more than 10,000 patients in 15 countries, including partnerships with a dozen Australian hospitals and clinics”.5
Foundayo is available on private prescription, not through the Pharmaceutical Benefits Scheme, however Dr Simon said Lilly is “working with the Federal Government to explore ways to broaden access to Foundayo and other innovative medicines.”
A private prescription for Foundayo can be filled by a pharmacist in a community pharmacy or through the LillyDirect service.
References
- Therapeutic Goods Administration. Australia. Foundayo (orforglipron). November 2026.
- Australian Institute of Health and Welfare: Overweight and obesity. Accessed October 2026.
- Australian Institute of Health and Welfare: Diabetes: Australian facts. Accessed October 2026.
- Australian Institute of Health and Welfare: Living with overweight or obesity overtakes tobacco as new leading burden of disease risk factor. Accessed October 2026.
- Lilly Australia. Data on file.
